Healthcare / BiotechnologyNasdaqGM
$8.05
+0.14 (+1.77%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-12.0M · quality 64.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$34M
P/E
N/A
•EV/EBITDA
N/A
•ROE
319.1%
↑Gross Margin
N/A
•Debt/Equity
-0.91
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
0.47x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-26.3M · FCF $-12.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Net Income | $-26.3M | $-26.3M | $-13.7M | $-60.5M | $4.4M | — |
| EBITDA | $-25.6M | $-25.6M | $-13.1M | $-58.9M | $4.4M | — |
| EPS | -8.08 | -8.08 | -3.50 | -19.12 | 1.84 | — |
| Balance Sheet | ||||||
| Debt/Equity | -0.91 | -0.91 | -0.43 | -1.01 | 0.12 | — |
| Current Ratio | 0.29 | 0.29 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-12.4M | $-12.4M | $-12.0M | $-8.3M | $-215395.00 | — |
| Returns | ||||||
| ROE | 319.1% | 319.1% | 205.7% | 64.0% | 1.3% | — |
| Valuation | ||||||
| P/E | — | — | — | — | 281.19 | — |
| EV/EBITDA | — | — | — | — | 290.24 | — |
| P/B | — | — | — | — | 3.62 | — |
| Growth & Yield | ||||||
| EPS Growth | -130.9% | -130.9% | 81.7% | -1141.2% | — | — |
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-87.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-3.50 → -8.08
Residual
-87.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.